Results 81 to 90 of about 44,692 (253)

Multifunctional lipid-based nanocarriers with antibacterial and anti‐inflammatory activities for treating MRSA bacteremia in mice

open access: yesJournal of Nanobiotechnology, 2021
Background Bacteremia-induced sepsis is a leading cause of mortality in intensive care units. To control a bacterial infection, an immune response is required, but this response might contribute to organ failure.
Chia-Chih Liao   +6 more
doaj   +1 more source

A review on medical plants affecting Staphylococcus aureus [PDF]

open access: yes, 2016
Background and aims: Infectious diseases are among the most important causes of mortality around the world and according to the WHO report 10.5 million cases of death were happened due to infections.
Motamedi, Hossein., Soltani Fard, Elahe.
core  

Dithiolopyrrolone Natural Products : Isolation, Synthesis and Biosynthesis [PDF]

open access: yes, 2013
Peer reviewedPublisher ...
Deng, Hai   +3 more
core   +2 more sources

A systematic scoping review of metrics utilized to measure antibiotic consumption in hospital settings

open access: yesBritish Journal of Clinical Pharmacology, EarlyView.
Abstract Antimicrobial stewardship (AMS) programs were introduced to promote the judicious use of antimicrobials and to combat antimicrobial resistance. Quantifying antibiotic consumption is an important part of AMS initiatives to achieve these objectives.
Marjan Kandimahforoujaki   +3 more
wiley   +1 more source

Actinomycetes Producing Anti-Methicillin Resistant Staphylococcus aureus from Soil Samples in Nakhon Si Thammarat

open access: yesWalailak Journal of Science and Technology, 2011
A total of 64 different isolates of Actinomycetes were isolated from soil samples in Nakhon Si Thammarat. The anti-MRSA activity of Actinomycetes isolates was examined using agar plug and agar well diffusion methods.
Sumeth NAORUNGROTE   +3 more
doaj   +1 more source

β-Lactam Resistance Mechanisms of Methicillin-Resistant Staphylococcus aureus [PDF]

open access: yes, 2017
In vitro and in vivo activity of amoxicillin and penicillin G alone or combined with a penicillinase inhibitor (clavulanate) were tested against five isogenic pairs of methicillin-resistant Staphylococcus aureus (MRSA) producing or not producing ...
Bille, Jacques   +3 more
core  

Therapeutic drug monitoring of antimicrobials in a paediatric setting: A retrospective single‐centre study

open access: yesBritish Journal of Clinical Pharmacology, EarlyView.
Aims Paediatric pharmacokinetics differ significantly from adults due to age‐related physiological changes, necessitating precise dose adjustments. However, data on therapeutic drug monitoring (TDM) implementation in paediatric setting remain limited.
Gianluca Gazzaniga   +20 more
wiley   +1 more source

Phenotypic and Genotypic Characteristics of Methicillin-Resistant Staphylococcus aureus (MRSA) Related to Persistent Endovascular Infection. [PDF]

open access: yes, 2019
Persistent methicillin-resistant Staphylococcus aureus (MRSA) bacteremia (PB) represents an important subset of S. aureus infection and correlates with poor clinical outcomes.
Bayer, Arnold S   +3 more
core   +1 more source

Evaluating the ototoxicity of an anti-MRSA peptide KR-12-a2

open access: yesBrazilian Journal of Otorhinolaryngology, 2018
Methicillin-resistant staphylococcus aureus is an emerging problem for the treatment of chronic suppurative otitis media, and also for pediatric tympanostomy tube otorrhea. To date, there are no effective topical antibiotic drugs to treat methicillin-resistant staphylococcus aureus otorrhea.In this study, we evaluated the ototoxicity of topical KR-12 ...
Sung, Chung Man   +4 more
openaire   +5 more sources

Lack of improvement after short‐term topical antistaphylococcal endolysin SA.100 therapy in patients with mild‐to‐moderate atopic dermatitis: Results from a randomized, vehicle‐controlled trial

open access: yesBritish Journal of Clinical Pharmacology, EarlyView.
Abstract Atopic dermatitis (AD) is a chronic immune‐mediated inflammatory skin disease. An overgrowth of Staphylococcus aureus (S. aureus) and decreased microbial diversity is apparent in 70%–90% of AD patients. SA.100 is a recombinant endolysin targeting S. aureus that might be a novel treatment for patients with mild‐to‐moderate AD.
Laura W. J. van der Meulen   +15 more
wiley   +1 more source

Home - About - Disclaimer - Privacy